Antigenics to Present at the UBS 2008 Global Life Sciences Conference
Posted on: Monday, 15 September 2008, 09:00 CDT
Antigenics Inc. (NASDAQ: AGEN) today announced that Garo Armen, Ph.D., the company's chairman and chief executive officer, will present at the UBS 2008 Global Life Sciences Conference at the Grand Hyatt New York on Monday, September 22, 2008 at 8:00 a.m. Eastern Time.
Dr. Armen will provide an overview of the company and its priority development programs, including Oncophage(R) (vitespen) therapeutic cancer vaccine and QS-21(TM) vaccine adjuvant.
The audio portion of the presentation will be webcast live on the company's website at www.antigenics.com and will be archived there for approximately 30 days following the presentation.
About Antigenics
Antigenics (NASDAQ: AGEN) is a biotechnology company working to develop treatments for cancers and infectious diseases. The company's investigational product portfolio includes Oncophage(R) (vitespen), a patient-specific therapeutic cancer vaccine being evaluated in several indications; Aroplatin(TM) (L-NDDP), a liposomal, third-generation platinum chemotherapeutic; AG-707, a therapeutic vaccine for the treatment of genital herpes; and QS-21 Stimulon(R), an adjuvant being evaluated by Antigenics' collaborative partners in approximately 15 clinical stage vaccines. For more information, please visit www.antigenics.com.
Source: Business Wire
Related Articles
- Antigen Discovery, Inc. Awarded Grant for Chlamydia Vaccine Development
- ImmunoVaccine Technologies Partners with FIT Biotech to advance a therapeutic HIV vaccine
- Multi-Pronged Therapeutic Cancer Vaccine Regimen to Be Studied in Melanoma Patients
- PharmAthene Response to DHHS Request for Proposals for Recombinant Protective Antigen Anthrax Vaccine Deemed Technically Acceptable and Within Competitive Range for Procurement Consideration
- PharmAthene Submits Response to DHHS Request for Proposals for SparVax(TM) - A Recombinant Protective Antigen Vaccine
- Generex Biotechnology Vaccine Strategy Presented at International Conference in London
- Impacts of BARDA and OPHEMC's Plan on Biodefense Countermeasures to Be Hot Topic at 5th Annual Biodefense Vaccines &Amp; Therapeutics Conference
- Avax Cleared to Launch Cancer Vaccine Trial
- AVAX Technologies Launches Global Phase III Registration Clinical Trial of M-Vax in Metastatic Melanoma
- Can Therapeutic Vaccines Fulfill Their Promise?
 |
 |
User Comments (0)
RSS Feeds